Kornimate/medical-research-clean huggingface dataset:
yoga and mindfulness for chronic low back pain: a randomized controlled trial

Conditions: Chronic Low-back Pain (cLBP)

Summary: chronic low back pain (clbp) is a leading cause of disability, significantly impacting quality of life and work productivity. traditional treatments often provide limited relief, necessitating alternative approaches. this multicenter, parallel-arm, randomized controlled trial (rct) aims to evaluate the efficacy of sphinx pose yoga therapy (yoga), mindfulness-based stress reduction (mbsr), and their combination in managing clbp among healthcare providers (hcps). participants will be randomly assigned to one of four groups: group a (yoga therapy): sphinx pose yoga therapy, practiced three times per week. group b (mbsr): weekly mindfulness meditation, body scan, and gentle stretching. group c (usual care): standard treatment guidelines as per the back book. group d (combined yoga \& mbsr): integrated approach, practiced twice per week. the study will assess pain intensity, functional disability, quality of life, physiological markers, mental health, and heart rate variability. outcomes will be measured at baseline (week 0), post-intervention (week 12), and follow-up (week 24). the trial aims to determine whether yoga, mbsr, or their combination provides superior benefits over usual care in clbp management.


Eligibility criteria:
inclusion criteria: * both genders between 25 to 45 years of age. * subjects having low back pain complaints and have visited the healthcare provider in recent days. * numerical pain rating (npr) scale score ≥ 2 for their pain intensity. * roland morris disability questionnaire subject's score should be ≥ 4. * fear avoidance beliefs questionnaire (fabq) work subscale score must be \< 19. exclusion criteria: * subjects with high risk for physical injuries during exercise. * pregnant and/or lactating females. * subjects with musculoskeletal disorders.

Keywords: chronic low back pain yoga therapy mindfulness-based stress reduction sphinx pose functional disability
long-circulating liposomal prednisolone versus pulse intramuscular methylprednisolone in patients with active rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: trial to study the safety of a single, intravenous administration of long-circulating liposomal prednisolone disodium phosphate in patients with active rheumatoid arthritis.

a proof of concept, dose-escalating trial to study the safety of a single, intravenous administration of long-circulating liposomal prednisolone disodium phosphate in patients with active rheumatoid arthritis. secondary goals: to compare the therapeutic effect of this intervention with that of a single intramuscular administration of 120 mg methylprednisolone (depo-medrol, pharmacia). the latter is commonly used in the clinics as bridging therapy. to assess the effect of these interventions at the synovial tissue level. on the longer term, the goal of liposomal corticosteroids is to achieve an increased efficacy/safety ratio compared to standard treatment with free corticosteroids.

Eligibility criteria:
inclusion criteria: in order to be enrolled in the study a patient must: be aged 18 years or older fulfill the revised 1987 ara criteria for the classification of ra have an active ra as defined by a modified disease activity score (das28) of more than 3.2 have been on stable treatment with disease modifying anti-rheumatic drugs within 12 weeks prior to trial initiation be able and willing to give voluntary written informed consent the indication for bridging therapy with systemic corticosteroids has been established by the caring rheumatologist - exclusion criteria: the patient must not have been treated with oral corticosteroids within 2 weeks prior to baseline or with intraarticular or intramuscular corticosteroids within 8 weeks prior to baseline have diabetes mellitus or abnormal renal, liver or haematological tests have a clinically severe or unstable medical condition involving cardiac, pulmonary, liver and endocrine disorders or malignancies have a previous history of bleeding or infectious disorders be currently pregnant or breastfeeding -

Keywords: rheumatoid arthritis long circulating liposomes
perception of fatigue among surgeons during night shifts

Conditions: Fatigue

Summary: the aim of this study was to illustrate surgeons' own perception of fatigue and the impact they felt it had on their performance. this was accomplished through a focus group study, where 13 surgeons participated.


Eligibility criteria:
inclusion criteria: * doctors working at department of surgical gastrointerology, who gave informed consent exclusion criteria: * withdrawal of consent

Keywords: focus group study sleep deprivation surgery
effect of nature based sounds' intervention on agitation and anxiety of patients admitted in intensive care units.

Conditions: Agitated; State, Acute Reaction to Stress; Anxiety

Summary: effect of nature based sounds' intervention on agitation and anxiety of patients admitted in intensive care units of mmims\&r hospital, mullana, ambala

introduction: continue stay in icu can lead to sleep disturbances and poor stress management that may result in client's inability to adjust with the situations and use of medical support. this experience may lead to increase agitation, anxiety as well as physiological stress of client, decrease comfort level and increase recovery time as well as hospital stay. there has been great emphasis on non-pharmacological methods that decrease anxiety and stress since they are very appropriate and affordable. objectives: the objective of the study was to assess the effect of nature based sounds on agitation and anxiety of patients admitted in intensive care units. methodology: a randomized controlled trial with pretest posttest control group design was used. sixty patients from surgical intensive care unit and were selected conveniently and randomly assigned into experimental and control group using lottery method. data was collected by agitation behavior assessment scale and beck anxiety inventory.

Eligibility criteria:
inclusion criteria: 1. willing to participate in the study. 2. in age group of 18 -75 years. exclusion criteria: 1. patients who were not having agitated behavior, normal anxiety and normal physiologic stress scores. 2. patients who were taking anti-hypertensive drugs, anti-depressants drugs and sedatives. 3. who could not response verbally or non-verbally in response to sample characteristics performa and beck anxiety inventory. 4. patients who were having psychiatric or neurological illness.

Keywords: nature based sounds agitation anxiety patients intensive care units
evaluation of cipro inhale in patients with non-cystic fibrosis bronchiectasis

Conditions: Bronchiectasis

Summary: the purpose of this study is to find out if bacterial load in the airways can be reduced after inhalation of ciprofloxacin for 28 days.

safety issues are addressed in the ae section. there is no standardised and unanimously accepted definition of exacerbation in copd; 4 definitions are widely used: (1) using a combination of 3 cardinal symptoms: increased dyspnea, sputum volume, and sputum purulence; (2) looking at the presence of the following patterns of symptoms during \>=2 consecutive days: either 2 or more of 3 major symptoms (increase in dyspnoea, sputum volume and sputum purulence); or any 1 major symptom together with any 1 minor symptom (increase in nasal discharge, wheeze, sore throat, cough or fever); (3) a sustained worsening of the patient's condition, from the stable state and beyond normal day-to-day variations, that is acute in onset and necessitates a change in regular medication in a patient with underlying copd; (4) a complex of respiratory events (i.e. cough, wheezing, dyspnoea or sputum production) lasting \>=3 days.

Eligibility criteria:
inclusion criteria: * patients with a proven and documented diagnosis of non-cystic fibrosis idiopathic or post pneumonic bronchiectasis * stable pulmonary status and stable regimen of standard treatment at least for the past 30 days exclusion criteria: * forced expiratory volume 1 \ 80% * allergic bronchopulmonary aspergillosis * immunodeficiency disease requiring immunoglobulin replacement * inflammatory bowel disease

Keywords: ciprofloxacin airway infection bronchiectasis
heart surgery in atrial fibrillation and supraventicular tachycardia

Conditions: Atrial Fibrillation

Summary: atrial fibrillation is the most common cardiac arrhythmia, the incidence of which increases drastically with age. as more and more elderly patients undergo heart surgery, the proportion of patients in this population will increase. atrial fibrillation has been shown to be a poor prognostic factor in several surgical situations. the aim of our study was to assess long-term mortality among patients with preoperative af under various cardiac surgery settings, with a particular emphasis on the strategy of coronary revascularization.


Eligibility criteria:
inclusion criteria: * referred for heart surgery, * preoperative atrial fibrillation exclusion criteria: * age\<18 years old

Keywords: atrial fibrillation, heart surgery, cabg, valve surgery, preoperative, mortality, grafts
cefiderocol in the treatment of multidrug-resistant gram-negative bacilli infections, a retrospective study

Conditions: Multidrug Resistant Bacterial Infection

Summary: cefiderocol is a new antibiotic from the siderophore cephalosporin family for which there are few real-life data on its use in the treatment of infections with multidrug-resistant gram-negative bacilli. the circulation of bacterial strains multi-resistant to antibiotics is important at the strasbourg university hospital, so the investigators wish to report their local experience of the 1st uses of cefiderocol in the treatment of infections with multi-resistant gram-negative bacilli to antibiotics in order to better clarify the use of this antibiotic (therapeutic indication, method of administration)


Eligibility criteria:
inclusion criteria: * adult patient (≥18 years old) * taken care of in the hus and treated as part of routine care with cefiderocol between 04/01/2020 and 08/31/2022. * subjects who have not expressed their opposition to the reuse of their data for scientific research purposes. exclusion criteria: - patient who has expressed his opposition to the retrospective reuse of his data for scientific research purposes.

Keywords: multidrug resistant bacterial infections gram-negative bacilli infections cefiderocol antibiotics
hyperglycemia in renal transplantation

Conditions: Diabetes; End Stage Renal Disease

Summary: based on multiple prior studies, kidney transplant recipients with diabetes are at higher risk for poor initial graft function after transplant. our study is designed to determine if tight blood sugar control around the time of kidney transplant will improve short term graft function.

population- our study population will include all adult diabetic patients undergoing deceased donor renal transplantation or living donor transplantation in which a swap requires transportation and resulting cold storage time. this will ensure a reasonable incidence of our primary outcome (poor short term graft function) and eliminate the potential risk of treating non-diabetic patients with insulin infusions. patients already enrolled in a drug trial designed to study the impact of the drug on graft function will be excluded. study design- this will be a randomized control trial. recipients will be randomized to either tight peri-operative glucose control or standard management. methods randomization protocol- in order to ensure that patients are equally distributed between groups, we will use block randomization. blocks of 4 patients will be created with the total number of experimental versus control assignments being equal across blocks. patients will then be randomly assigned to a block. interventions- the study group will be treated with an insulin infusion to achieve tight glycemic control (100-140mg/dl). each study patient will be started on an insulin infusion prior to their operation. this infusion will continue throughout the operation and for 24 hours after completion of the transplant. glucose control will then be left to the discretion of the primary team. the control group will be treated with bolus insulin based on a standard insulin sliding scale. outcomes aim 1- primary endpoint- our primary endpoint will be poor initial graft function defined by the occurrence of dgf (defined by a decrease in serum creatinine of \ 3 mg/dl 5 days after transplant without dialysis) secondary endpoint- secondary endpoints will include wound infection, length of hospital stay, 30 day mortality, hypoglycemic episodes(glucose \<70 mg/dl) and stroke. aim 2- primary endpoint- our primary endpoints will be acute rejection at 90 days and graft survival/renal function at 3months, 6months and then yearly. statistical analysis- data will be described as means with standard deviations or percentages with ranges based on whether the data represent continuous or categorical variables. the t-test and chi-squared test will be used to test hypotheses.

Eligibility criteria:
inclusion criteria: * adult patients * diabetic * end stage renal disease undergoing cadaveric renal transplant exclusion criteria: * enrolled in concurrent study to test impact of a drug on graft function after transplant

Keywords: diabetes kidney transplant end stage renal disease delayed draft function
post marketing surveillance of pirespa® tab 200mg (pirfenidone) for evaluating the safety and efficacy

Conditions: Idiopathic Pulmonary Fibrosis

Summary: post-marketing surveillance of pirfenidone

pirfenidone (pirespa®) is an anti fibrotic drug, which was approved in 2012 in the republic of korea for the treatment of patients with idiopathic pulmonary fibrosis (ipf). a post-marketing survey was conducted following the approval to obtain data on the safety and efficacy of pirfenidone for ipf treatment in real-world practice.

Eligibility criteria:
inclusion criteria: * among patients diagnosed as idiopathic pulmonary fibrosis, only those who have used the testing drug under the general medical conditions for a certain investigation period after the beginning of the investigation and also signed a the "personal information utilization agreement" form. however, for those who have already received the drug before the beginning of the investigation, only the subjects whose medical record can be used are included. exclusion criteria: 1. subjects who is hypersensitive to the active ingredient or additives of this drug 2. subjects who have severe hepatopathy 3. subjects who have severe renal disorder (creatinine clearance\<30ml/min) or a terminal renal disease treated by dialysis 4. subjects who received a combined treatment of fluvoxamine 5. subjects who have genetic problems, such as galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption
interventions to improve the hiv prep cascade among methamphetamine users

Conditions: HIV/AIDS; Adherence, Medication; Drug Use

Summary: despite increasing knowledge about and use of prep nationally, hiv continues to have disproportionate impact among cisgender men and transgender persons who have sex with men and transgender persons (msm/tg), with methamphetamine (meth)-users being at particularly high risk. building on their preliminary work, the investigators will pilot text messaging and peer navigation interventions to support prep use among meth-using msm/tg with potential to be cost-effective, scalable, and easily adaptable.

despite increasing knowledge about and use of prep nationally, hiv continues to have disproportionate impact among cisgender men and transgender persons who have sex with men and transgender persons (msm/tg), with methamphetamine (meth)-users being at particularly high risk. despite apparent high levels of prep knowledge and exceptional insurance and medication coverage, few meth-users in western wa have enrolled in local prep programs. the investigators' preliminary work with meth-using msm/tg has identified both traditional barriers to prep and barriers specific for meth users, including competing priorities (e.g., getting high); lack of regularity in daily schedules leading to difficulties complying with appointments and medication adherence; and concomitant wellness and social concerns, notably depression and meth-related stigma. additional work is needed to develop new strategies to increase prep uptake and support persistence and adherence among meth-using msm/tg. building on their preliminary work, the investigators will pilot text messaging and peer navigation interventions to support prep use among meth-using msm/tg with potential to be cost-effective, scalable, and easily adaptable. the first, peer navigation, has been studied in arv treatment and has been proposed for prep. the second, text messaging, has been shown to increase arv and prep adherence.

Eligibility criteria:
inclusion criteria: * meets the clinic's eligibility criteria for prep * 18 years of age or older * hiv-negative * cisgender man or individual on the trans gender variant spectrum who has sex with men * ability to understand, read, and speak english * reports meth use in the past 3 months * has a cell phone able to send and receive text messages exclusion criteria: * prep use in the prior month, * discomfort or anxiety with regards to text messaging. * has any circumstances that, based on the study staff's opinion, would preclude provision of informed consent, make participation unsafe, or make it unlikely the participant would be able to participate for 6 months.

Keywords: pre-exposure prophylaxis (prep) methamphetamine
submandibular gland preservation in neck dissection

Conditions: Neck Dislocation; Oral Cancer

Summary: trial design: a randomized controlled trial. eligibility criteria for participants: patients with primary early stage oral squamous cell carcinoma. exclusion criteria: cancer of the floor of the mouth. interventions: submandibular gland is preserved during neck dissection for patients of the experimental group; submandibular gland is removed during neck dissection for patients of the control group. primary parameters: survival rate, mortality rate


Eligibility criteria:
inclusion criteria: primary oral squamous cell carcinoma of early stage (t1n0 and t2n0). exclusion criteria: cancer of the floor of the mouth.
smv + sof with/without rbv for ifn-ii patients with chc

Conditions: Hepatitis C

Summary: prior trials have shown that many g1 chc patients are ineligible or intolerant to pegylated (peg)-based regimens due to prior severe side effects, worsening of cytopenias, exacerbation of underlying psychiatric disorders, or autoimmune disorders. these patients will not be candidates for treatment with the approvals of smv and sof in early 2014 due to the combination with peg-regimens. results of the cosmos study suggest that these patients are likely to have excellent responses to smv+sof with or without rbv with 12 weeks of therapy, and that 24 weeks are unnecessary. this trial is designed to rapidly enroll and be completed in order to confirm this hypothesis.


Eligibility criteria:
inclusion criteria: 1. targeted at least 20% enrollment of patients with cirrhosis 2. adults \>/= age 18 years. 3. active infection with hepatitis c virus (hcv) genotype 1 4. must have health insurance that covers therapy with sof+rbv 5. female patients of childbearing age must have a negative pregnancy test prior to initiating therapy, use at least two effective methods of contraception during treatment, and undergo monthly pregnancy tests. 6. patients must be either ifn-ineligible due to psychiatric, autoimmune, neurological, or other causes that are confirmed appropriate by the pi; or, 7. ifn-intolerant due to flu-like symptoms, psychiatric problems, cytopenia or other causes deemed appropriate by the pi. exclusion criteria: 1. presence of hiv co-infection 2. presence of hepatocellular carcinoma (hcc) 3. prior organ transplantation 4. any history of hepatic decompensation 5. patients taking any of the following medications: * anticonvulsants- carbamazepine, oxcarbazepine, phenobarbital, or phenytoin. * anti-infectives-erythromycin, clarithromycin, or telithromycin. * antifungals- systemic itraconazole, ketoconazole, posaconazole, fluconazole, or voriconazole. * antimycobacterials- rifampin, rifabutin or rifapentine. * corticosteroids- systemic dexamethasone. * propulsives- cisapride. * herbals- milk thistle or st. john's wart. 6. patients that have been exposed to direct acting anti-viral agents 7. patients with severe renal impairment (estimated glomerular filtration rate (egfr) \<50 ml/min/1.73m2) or with end stage renal disease (esrd). 8. patients with platelet count \<50 x109/l, hemoglobin \<10 g/dl, or neutrophils \<0.5 x109/l. 9. women who are pregnant. 10. men whose partners are pregnant or plan on becoming pregnant.
calibration of mr and pet-mr imaging protocols at ric

Conditions: Cancer; Coronary Artery Disease

Summary: this is a protocol to facilitate on-site calibration of the technical aspects of the siemens biograph mmr (molecular mr) positron emission tomography-magnetic resonance (pet-mr) scanner and the 3t siemens vida mr scanner at the cedars-sinai medical center (csmc) biomedical imaging research institute (biri) research imaging core after scanner installation. the mmr is a fda-approved standard clinical device (non-experimental) and will be used in accordance with clearance and approval from the fda. the vida is a state-of-the-art fda approved scanner and will be clinically licensed within a short time.

pet-mr protocol on the biograph mmr: this protocol requires the use of a radioisotope. to avoid administering radioisotope solely for the purposes of this calibration, we will recruit 20 patients from the clinical population at the s. mark taper foundation imaging center at csmc who are already receiving an isotope dose for their standard-of-care examination and are willing to be scanned at the research imaging core on the same day right after their clinical exam. subjects who are having a pet-mr after receiving fdg will have the same body part scanned as they did for clinical testing. mr-only protocol on the biograph mmr:to set up mr-only protocols, we will enroll 20 volunteers for mr-only on the mmr scanner. this is a standard mr scan with no isotope involved. those volunteers who are participating in the mr-only scan will have major body parts and organs scanned as needed for calibration. mr imaging on the siemens vida 3t scanner: applications training is taking place and we will build clinical protocols in the future

Eligibility criteria:
inclusion criteria: * age ≥18 years. * for mr-pet calibration: outpatient undergoing standard-of-care 18fdg-pet at s. mark taper foundation imaging center at csmc * for mr-only calibration: volunteers who are responding to approved advertising to volunteer at the biri research imaging core for research mr exclusion criteria: * age \< 18 years * pregnancy * any contraindications to mr imaging. * any contraindication to mri, including metallic implants (valve replacement, pacemaker, implantable cardiac defibrillator, metallic spine material), intracranial clips, metallic fragments in eyes, and claustrophobia.

Keywords: magnetic resonance imaging mri positron emission tomography pet pet-mr mmr